Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Collplant Holdings ( (CLGN) ) has shared an announcement.
On February 5, 2026, CollPlant Biotechnologies announced it had entered into a definitive agreement for a $2.0 million registered direct offering, issuing 1,600,000 ordinary shares at $1.25 per share, alongside a concurrent private placement of unregistered series A and series B warrants to purchase up to an additional 3,200,000 ordinary shares at the same exercise price. The transaction, expected to close on or about February 6, 2026 subject to customary conditions and led by H.C. Wainwright & Co. as exclusive placement agent, will provide CollPlant with additional capital for general corporate purposes, including working capital and funding its research and development programs, reinforcing its financing base as it advances its rhCollagen-based platforms in regenerative medicine and medical aesthetics.
The most recent analyst rating on (CLGN) stock is a Sell with a $2.00 price target. To see the full list of analyst forecasts on Collplant Holdings stock, see the CLGN Stock Forecast page.
Spark’s Take on CLGN Stock
According to Spark, TipRanks’ AI Analyst, CLGN is a Neutral.
The score is held down primarily by weak financial performance—large ongoing losses, heavy cash burn, and a shrinking equity base despite some TTM revenue and gross margin improvement. Technicals provide partial support with a stronger short-term trend, but longer-term trend and momentum are mixed. Valuation remains unattractive due to negative earnings and no dividend yield.
To see Spark’s full report on CLGN stock, click here.
More about Collplant Holdings
CollPlant Biotechnologies is an Israel-based regenerative and aesthetic medicine company focused on 3D bioprinting of tissues and organs and medical aesthetics. Its products are built on proprietary plant-based genetic engineering technology that produces recombinant human collagen (rhCollagen), targeting applications in tissue repair, aesthetics, and organ manufacturing, including a commercialization agreement for dermal and soft tissue fillers with Allergan, an AbbVie company.
Average Trading Volume: 26,582
Technical Sentiment Signal: Sell
Current Market Cap: $20.47M
For an in-depth examination of CLGN stock, go to TipRanks’ Overview page.